Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 2/20 | 0.34 |
| ▸ | MAP3K12 | Q12852 | 3/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.33 |
| ▸ | BCR | P11274 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 3/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.30 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.30 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18623818 | 0.84 | KDR (0.36) | TGFBR1MAOAMAOB | |
| SCHEMBL18623808 | 0.83 | NPC1 (0.47) | TGFBR1GRM5 | |
| SCHEMBL18623812 | 0.82 | KDM1A (0.35) | MAOAMAOB | |
| SCHEMBL17080356 | 0.81 | GRM5 (0.34) | TGFBR1GRM5EGLN2 | |
| SCHEMBL18623810 | 0.81 | KDR (0.43) | MAOAMAOBMAP4K4 | |
| SCHEMBL18623804 | 0.80 | TGFBR1 (0.35) | TGFBR1 | |
| SCHEMBL18623807 | 0.80 | MAP3K12 (0.34) | ABL1MAP3K12GRM5PDE4BPDE4D | |
| SCHEMBL18623817 | 0.79 | MAPT (0.37) | GRM5MAOAMAOB | |
| SCHEMBL18623813 | 0.78 | KDM4E (0.41) | TGFBR1 | |
| SCHEMBL18623819 | 0.78 | DYRK1A (0.42) | TGFBR1GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9896454-B2 | Microbiocidal heterobicyclic derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2018-02-20 | — | — | US | disclosed |
| US-9896454-B2 | Microbiocidal heterobicyclic derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2018-02-20 | — | — | US | disclosed |
| US-9896454-B2 | Microbiocidal heterobicyclic derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2018-02-20 | — | — | US | disclosed |
| EP-3114127-B1 | MICROBIOCIDAL HETEROBICYCLIC DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2017-11-29 | — | — | EP | disclosed |
| US-20170073346-A1 | MICROBIOCIDAL HETEROBICYCLIC DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2017-03-16 | — | — | US | disclosed |
| US-20170073346-A1 | MICROBIOCIDAL HETEROBICYCLIC DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2017-03-16 | — | — | US | disclosed |
| US-20170073346-A1 | MICROBIOCIDAL HETEROBICYCLIC DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2017-03-16 | — | — | US | disclosed |
| EP-3114127-A1 | MICROBIOCIDAL HETEROBICYCLIC DERIVATIVES | Syngenta Participations AG (CH) | 2017-01-11 | — | — | EP | disclosed |
| WO-2015132133-A1 | MICROBIOCIDAL HETEROBICYCLIC DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2015-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170073346-A1 | MICROBIOCIDAL HETEROBICYCLIC DERIVATIVES | MSR1, C1R, C3AR1 | ABL1 3690/4885MAP3K12 4705/4885TGFBR1 714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.